Urinary Antigen Test for Stretococcus Pneumoniae Serotype Prevalence in Community Acquired Pneumonia
Sponsor
Chinese University of Hong Kong (Other)
Overall Status
Recruiting
CT.gov ID
NCT05374018
Collaborator
(none)
1,800
1
30.9
58.2
Study Details
Study Description
Brief Summary
This is an epidemiology study for the prevalence and serotypes of pneumococcus pneumoniae in hospitalized patients with community acquired pneumonia (CAP). The serotypes of the pneumococcus pneumoniae will be determined by a urinary antigen assay
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
1800 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Prospective Study to Evaluate Stretococcus Pneumoniae Serotype Prevalence in Community Acquired Pneumonia in Hong Kong Using a Urinary Kit
Actual Study Start Date
:
Dec 1, 2021
Anticipated Primary Completion Date
:
Dec 31, 2023
Anticipated Study Completion Date
:
Jun 30, 2024
Outcome Measures
Primary Outcome Measures
- prevalence of strep pneumonia [2 years]
to determine prevalence
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
Admitted with signs and symptoms suggestive of pneumonia which include one or more of the followings:
-
fever
-
CXR changes with consolidation, increased alveolar shadowing or hazziness
-
respiratory symptoms like increase shortness of breath, cough with sputum Raised inflammatory markers suggesting of bacterial infection with either increased white cell count or C-reactive protein, or both
Exclusion Criteria:
- Nosocomial pneumonia which is acquired >= 48 hours after hospital admission. Pneumonia which are already known to be caused by pathogens other than pneumococcus pneumoniae.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Medicine and Therapeutics, Prince of Wales Hospital, CUHK | Shatin | Hong Kong |
Sponsors and Collaborators
- Chinese University of Hong Kong
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
To Kin Wang,
Prof.,
Chinese University of Hong Kong
ClinicalTrials.gov Identifier:
NCT05374018
Other Study ID Numbers:
- CREC 2020.34
First Posted:
May 13, 2022
Last Update Posted:
May 13, 2022
Last Verified:
May 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: